颈内动脉狭窄病变是脑卒中的重要原因，颈动脉支架治疗是对狭窄颈内动脉最为重要的干预措施之一。但支架内再狭窄是急需解决的问题。人类基因组计划的实施，使得基因治疗在支架内再狭窄的防治中成为可能。我们前期临床和基础研究证实增加PPARγ在支架局部组织的表达对于治疗支架内再狭窄可能具有重要的意义。基于以上研究，本申请拟将PPARγ基因和VEGF基因(可促进支架再内皮化)共支架携载，通过使用基于聚甲基丙烯酸缩水甘油酯（PGMA）的聚阳离子型基因载体负载基因，并将核酸/载体复合物通过表面涂层技术固定于血管支架表面，实现核酸/载体复合物的缓释/控释，将目标基因高效地递送到血管内皮细胞和血管平滑肌细胞内，并通过体内、体外实验评价基因治疗的效率与结果。通过本申请的研究，有望开拓预防支架内再狭窄和促进支架内皮化的新思路，拓宽聚阳离子型基因载体的临床应用范围，对于基因治疗在循环系统方面的应用具有很高的理论价值。

Carotid artery stenosis is an important cause of stroke, and carotid artery stenting is one of the most important interventions for the internal carotid artery stenosis. However, in-stent restenosis may happen, and should be solved urgently. With the implementation of the Human Genome Project, gene therapy might be used to prevent and treat in-stent restenosis. Our previous clinical and basic researches indicated that increased expression of PPARγin local tissues around stents might play an important role in the treatment of in-stent restenosis. Based on the results of the above studies, the present study aim to develop a PPARγgene and VEGF gene co-eluting stent using poly (glycidyl methacrylate) (PMGA)-based polycation gene vector; to immobilize the nucleic acid / carrier complex on the surface of stents using surface coating technology, resulting in slow/ controlled release of nucleic acid / carrier complex; and to efficiently deliver the target gene into vascular endothelial cells and vascular smooth muscle cells. The effect and outcome of gene therapy will be validated via in vivo and in vitro experiments. Through the present research, we expect to explore a new way to prevent in-stent restenosis and promote stent endothelialization, and broaden the clinical application scope of the polycationic gene vectors, which has a high theoretical value for the application of gene therapy in the circulatory system.